Are we ready to treat hepatitis C virus in individuals with opioid use disorder: Assessment of readiness in European countries on the basis of an expert-generated model
Standard
Are we ready to treat hepatitis C virus in individuals with opioid use disorder: Assessment of readiness in European countries on the basis of an expert-generated model. / Wright, Nat; Reimer, Jens; Somaini, Lorenzo; Roncero, Carlos; Maremmani, Icro; Simon, Nicolas; Krajci, Peter; Littlewood, Richard; D'Agnone, Oscar; Alho, Hannu; Rolland, Benjamin.
In: EUR J GASTROEN HEPAT, Vol. 29, No. 11, 11.2017, p. 1206-1214.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Are we ready to treat hepatitis C virus in individuals with opioid use disorder: Assessment of readiness in European countries on the basis of an expert-generated model
AU - Wright, Nat
AU - Reimer, Jens
AU - Somaini, Lorenzo
AU - Roncero, Carlos
AU - Maremmani, Icro
AU - Simon, Nicolas
AU - Krajci, Peter
AU - Littlewood, Richard
AU - D'Agnone, Oscar
AU - Alho, Hannu
AU - Rolland, Benjamin
PY - 2017/11
Y1 - 2017/11
N2 - Individuals with a history of injecting drugs have a high prevalence of chronic hepatitis C (HCV) infection. Many have a history of opioid use disorder (OUD). Despite novel treatments with improved efficacy and tolerability, treatment is limited in the group. A faculty of experts shared insights from clinical practice to develop an HCV care-readiness model. Evidence and expert knowledge was collected. Ten experts developed a model of three factors (with measures): 'healthcare engagement', 'guidance' and 'place'. Overall, 40-90% of individuals with OUD engage with drug treatment services. Ten of 12 HCV guidelines provided specific advice for the OUD population. Ten of 12 OUD care guidelines provided useful HCV care advice. In 11 of 12 cases, location of HCV/drug treatment care was in different places. This readiness assessment shows that there are important limitations to successful HCV care in OUD. Specific actions should be taken: maintain/increase access to OUD treatment services/opioid agonist therapy, updating HCV guidance, locate care in the same place and allow wider prescribing of anti HCV medicines.
AB - Individuals with a history of injecting drugs have a high prevalence of chronic hepatitis C (HCV) infection. Many have a history of opioid use disorder (OUD). Despite novel treatments with improved efficacy and tolerability, treatment is limited in the group. A faculty of experts shared insights from clinical practice to develop an HCV care-readiness model. Evidence and expert knowledge was collected. Ten experts developed a model of three factors (with measures): 'healthcare engagement', 'guidance' and 'place'. Overall, 40-90% of individuals with OUD engage with drug treatment services. Ten of 12 HCV guidelines provided specific advice for the OUD population. Ten of 12 OUD care guidelines provided useful HCV care advice. In 11 of 12 cases, location of HCV/drug treatment care was in different places. This readiness assessment shows that there are important limitations to successful HCV care in OUD. Specific actions should be taken: maintain/increase access to OUD treatment services/opioid agonist therapy, updating HCV guidance, locate care in the same place and allow wider prescribing of anti HCV medicines.
KW - Journal Article
U2 - 10.1097/MEG.0000000000000962
DO - 10.1097/MEG.0000000000000962
M3 - SCORING: Journal article
C2 - 28914697
VL - 29
SP - 1206
EP - 1214
JO - EUR J GASTROEN HEPAT
JF - EUR J GASTROEN HEPAT
SN - 0954-691X
IS - 11
ER -
